.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Federal Trade Commission
Teva
Boehringer Ingelheim
Deloitte
Farmers Insurance
AstraZeneca
Queensland Health
US Army
Accenture

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,324,174

« Back to Dashboard

Details for Patent: 8,324,174

Title:Compounds for enzyme inhibition
Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Inventor(s): Smyth; Mark S. (Foster City, CA), Laidig; Guy J. (Menlo Park, CA), Borchardt; Ronald T. (Lawrence, KS), Bunin; Barry A. (San Mateo, CA), Crews; Craig M. (New Haven, CT), Musser; John H. (San Carlos, CA)
Assignee: Onyx Therapeutics, Inc. (South San Francisco, CA)
Filing Date:Dec 22, 2011
Application Number:13/334,372
Claims:1. A method for preparing a compound having formula (II), or a pharmaceutically acceptable salt thereof: ##STR00029## wherein X is O; R.sup.2 and R.sup.4 are each isobutyl; R.sup.5 is selected from the group consisting of: (i) --NHC(.dbd.O)CH.sub.2OH; (ii) --NHC(.dbd.O)CH.sub.2OP(O)(O.sup.-Na.sup.+).sub.2; (iii) --NHC(.dbd.O)CH.sub.2N(CH.sub.3).sub.2; (iv) --NHC(.dbd.O)CH.sub.2-(1-piperidyl); (v) --NHC(.dbd.O)CH.sub.2-(cyclopropyl); and (vi) --NHC(.dbd.O)CH.sub.2CH.sub.2CH.sub.2N(CH.sub.3).sub.2; the method comprising reacting a first compound, or a salt thereof, having a first formula, which is selected from the group consisting of: ##STR00030## with a second compound, or a salt thereof, having a second formula: ##STR00031##

2. The method of claim 1, wherein the first compound has the formula: ##STR00032##

3. The method of claim 1, wherein the first compound has the formula: ##STR00033##

4. The method of claim 1, wherein the first compound has the formula: ##STR00034##

5. The method of claim 1, wherein the first compound has the formula: ##STR00035##

6. The method of claim 1, wherein the first compound has the formula: ##STR00036##

7. The method of claim 1, wherein the first compound has the formula: ##STR00037##

8. The method of claim 1, wherein reacting the first compound with the second compound is carried out in the presence of BOP or PyBOP and HOBt.

9. The method of claim 8, wherein reacting the first compound with the second compound is carried out in the presence of DIEA.

10. The method of claim 1, wherein the method further comprises mixing the compound having formula (I), or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers to form a composition.

11. The method of claim 10, wherein at least one of the one or more pharmaceutically acceptable carriers is a cyclodextrin.

12. The method of claim 10, wherein at least one of the one or more pharmaceutically acceptable carriers is a substituted or unsubstituted .beta.-cyclodextrin.

13. The method of claim 10, wherein the method further comprises adding an anti-oxidant.

14. The method of claim 13, wherein the anti-oxidant is citric acid.

15. A compound having formula (II), or a pharmaceutically acceptable salt thereof: ##STR00038## wherein X is O; R.sup.2 and R.sup.4 are each isobutyl; R.sup.5 is selected from the group consisting of: (i) --NHC(.dbd.O)CH.sub.2OH; (ii) --NHC(.dbd.O)CH.sub.2OP(O)(O.sup.-Na.sup.+).sub.2); (iii) --NHC(.dbd.O)CH.sub.2N(CH.sub.3).sub.2; (iv) --NHC(.dbd.O)CH.sub.2-(1-piperidyl); (v) --NHC(.dbd.O)CH.sub.2-(cyclopropyl); and (vi) --NHC(.dbd.O)CH.sub.2CH.sub.2CH.sub.2N(CH.sub.3).sub.2; prepared by a process as claimed in claim 1.

16. A composition prepared by a process as claimed in claim 10.

17. A method for preparing a compound having formula (II), or a pharmaceutically acceptable salt thereof: ##STR00039## X is O; R.sup.2- and R.sup.4 are each isobutyl; R.sup.5 is selected from the group consisting of: (i) ##STR00040## (ii) --NHC(.dbd.O)NHPh; and (iii) --NHC(.dbd.S)NHPh; and the method comprising: (a) reacting a first compound, or a salt thereof, having a first formula: ##STR00041## with a second compound, or a salt thereof, having a second formula: ##STR00042## in the presence of H.sub.2/Pd/C, to form a third compound, or a salt thereof, having a third formula: ##STR00043## and (b) reacting the third compound, or a salt thereof, with a fourth compound in the presence of trifluoroacetic acid, wherein the fourth compound is selected from the group consisting of: (i) 1,3,5-trimethyl-1-H-pyrazole-4-sulfonyl chloride; (ii) phenyl isocyanate; and (iii) phenyl isothiocyanate.

18. The method of claim 17, wherein the fourth compound is 1,3,5-trimethyl-1-H-pyrazole-4-sulfonyl chloride.

19. The method of claim 17, wherein the fourth compound is phenyl isocyanate.

20. The method of claim 17, wherein the fourth compound is phenyl isothiocyanate.

21. A compound having formula (II), or a pharmaceutically acceptable salt thereof: ##STR00044## X is O; R.sup.2- and R.sup.4 are each isobutyl; R.sup.5 is selected from the group consisting of: (i) ##STR00045## (ii) --NHC(.dbd.O)NHPh; and (iii) --NHC(.dbd.S)NHPh; prepared by a process as claimed in claim 17.

22. The method of claim 17, wherein the method further comprises mixing the compound having formula (I), or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers to form a composition.

23. The method of claim 22, wherein at least one of the one or more pharmaceutically acceptable carriers is a cyclodextrin.

24. The method of claim 22, wherein at least one of the one or more pharmaceutically acceptable carriers is a substituted or unsubstituted .beta.-cyclodextrin.

25. The method of claim 22, wherein the method further comprises adding an anti-oxidant.

26. The method of claim 25, wherein the anti-oxidant is citric acid.

27. A composition prepared by a process as claimed in claim 22.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Dow
McKinsey
Farmers Insurance
Citi
Medtronic
Cerilliant
Federal Trade Commission
Deloitte
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot